PHGUF - Orchard Therapeutics inks strategic deal to develop HSC gene therapy for hereditary angioedema

Orchard Therapeutics (ORTX) and Pharming Group (PHAR) announce a strategic collaboration to research, develop, manufacture and commercialize OTL-105, an investigational ex vivo autologous hematopoietic stem cell ((HSC)) gene therapy for the treatment of hereditary angioedema ((HAE)), a rare disorder that causes recurring swelling attacks in the face, throat, extremities and abdomen. Under the terms of the collaboration, Pharming has been granted worldwide rights to OTL-105 and will be responsible for clinical development, regulatory filings, and commercialization of the investigational gene therapy, including associated costs. In exchange, Orchard will receive an upfront payment of $17.5M comprising $10M in cash and a $7.5M equity investment from Pharming and is also eligible to receive up to $189.5M in milestone payments as well as mid-single to low double-digit royalty payments on future worldwide sales.Also, ORTX will lead the completion of IND-enabling activities and oversee manufacturing of OTL-105.In addition, both companies will explore the application

For further details see:

Orchard Therapeutics inks strategic deal to develop HSC gene therapy for hereditary angioedema